Pharming Technologies B.v.
Clinical trials sponsored by Pharming Technologies B.v., explained in plain language.
-
New drug shows promise for Long-Term control of rare immune disorders
Disease control Recruiting nowThis study is testing the long-term safety of a drug called leniolisib in people with primary immunodeficiency disorders linked to PI3K signaling. Participants are 12 people who already took leniolisib in a previous study and may benefit from continuing it. The goal is to see if …
Phase: PHASE2 • Sponsor: Pharming Technologies B.V. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug aims to ease fatigue in mitochondrial disease
Symptom relief Recruiting nowThis Phase 2 trial tests whether KL1333 can reduce fatigue and improve leg strength in adults with primary mitochondrial disease, a genetic condition that affects energy production. About 180 participants will receive either KL1333 or a placebo twice daily for 48 weeks. The study…
Phase: PHASE2 • Sponsor: Pharming Technologies B.V. • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC